HOME >> BIOLOGY >> NEWS
Animal studies show CA4P suppresses development and induces regression of ocular neovascularization

Watertown, Mass., July 31, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the results of independent animal studies demonstrating the potential role of the Company's lead compound, Combretastatin A4 Prodrug (CA4P), in preventing and treating certain retinal degenerative diseases. Findings of the study are published in the current issue of the peer-reviewed journal Investigative Ophthalmology and Visual Science (IOVS).

The studies were conducted at The Johns Hopkins University School of Medicine by a team of researchers including Peter A. Campochiaro, M.D., a professor of ophthalmology at the school's renowned Wilmer Eye Institute. Dr. Campochiaro and Assistant Professor of Ophthalmology Quan Dong Nguyen, M.D. are leading the current Phase I/II clinical trial of CA4P in patients with wet age-related macular degeneration, known as wet AMD. Between 2 million and 3 million people in the United States have significant vision loss caused by wet AMD.

"The pre-clinical research produced by Dr. Campochiaro and his colleagues, as well as several other pre-clinical ophthalmic models using CA4P, provided the impetus for OXiGENE to move CA4P into human trials at Johns Hopkins," said Fred Driscoll, OXiGENE's president and CEO. "We are very pleased that Dr. Campochiaro considered the data from this study compelling enough to take CA4P into trials at one of the world's leading research institutions."

The study was designed to gauge CA4P's ability to suppress the development of choroidal neovascularization (CNV), a condition in which aberrant blood vessels beneath the retina leak blood and fluid into the retina. CNV is the primary cause of severe vision loss in patients with retinal degenerative diseases such as wet AMD. Researchers conducted experiments using transgenic mice with CNV caused by an over expression of vascular endothelial growth factor in the retina (rho/VEGF mice) and mice with laser-induced rupture of Bruch's memb
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
31-Jul-2003


Page: 1 2

Related biology news :

1. Animal research suggests plant estrogens in soy do not increase breast cancer risk
2. Could vitamins raise levels of bad cholesterol? Animal study suggests they might
3. Animal studies show promise treating severe chronic pain
4. UF researcher: Animals think in their own way, but unlike humans
5. Animal study demonstrates carbon monoxide may help heart patients
6. Animals can be induced to cooperate if partners reciprocate and benefits accumulate
7. Animal study finds embryonic stem cells can repair heart muscle
8. Animal welfare can now be objectively measured
9. Animals regulate their numbers by own population density
10. UF researchers score gene therapy advance: Animal study shows high blood pressure prevented in future generations
11. Experimental Staph Vaccine Broadly Protective In Animal Studies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2019)... (PRWEB) , ... April 02, 2019 , ... ... and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base ... the anchor tenant at the University’s newly created biotechnology park in Galway, Ireland. ...
(Date:4/1/2019)... ... 01, 2019 , ... uBiome announces the issue of patent ... US Patent and Trademark Office on January 1, 2019 with a priority date ... Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. Jessica Richman, and Dr. Catalina Valdivia, ...
(Date:3/29/2019)... ... March 29, 2019 , ... ... a partnership to expand their broad tissue-based biomarker development capabilities, as well ... the terms of the agreement, the companies will offer a comprehensive set ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... ... After more than three months of renovation, Lajollacooks4u is set to reveal ... and modern lighting and fixtures, and will provide additional workspace for the many guests ... in the demand for our team-building events and cooking classes over the last eleven ...
(Date:4/8/2019)... ... April 08, 2019 , ... ... solutions, announced today the launch of their app integration solution, CT Cloud Unite. ... and contact-orientated applications while using CT Cloud Voice and Skype for Business solutions. ...
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, ... collaboration and dialogue, today announces its Boston CEO conference to be held May ... industry’s challenges and opportunities with high-level panels and discussions from past, present and ...
(Date:3/27/2019)... ... March 27, 2019 , ... Lachman is sponsoring the event on April ... Road, Dublin, Ireland. The executive team on site will be available to discuss strategies ... on the agenda this year. , Executives from Lachman participating at this year’s conference ...
Breaking Biology Technology:
Cached News: